Acciones de Tempus AI, Inc. (TEM) — ¿es un buen negocio?

Acciones de Tempus AI, Inc. (TEM) — ¿es un buen negocio? — InspectStocks

Cómo gana dinero

Diagnostic testing75 %
Data and applications25 %

Los porcentajes de ingresos son estimaciones para nine months ended September 30, 2026, no cifras de un informe oficial.

Compite con

Caris Life Sciences

Qué vende6

Tempus|xT
A test of cancer tissue that looks for gene changes that may help doctors understand a cancer and choose treatment.
Tempus|xF
A blood test that looks for cancer-related genetic material circulating in the blood.
Tempus|xG
Tests that look for inherited gene changes linked to cancer risk and other inherited conditions.

Mostrar 3 más

Insights
De-identified patient records and research tools that drug and biotechnology companies use to study diseases and develop medicines.
TIME Trial program
A service that helps doctors and drug companies find patients who may qualify for clinical trials.
Next
Software that checks patient information to help care teams spot missed tests or follow-up needs in cancer and heart care.

Quién se lo compra4

Doctors, genetic counselors, and hospitals order tests for patients; insurers, government health programs, patients, or the ordering institution may pay.
Pharmaceutical and biotechnology companies buy de-identified patient data, research tools, and analysis services.
Drug companies pay for help identifying patients who may qualify for clinical trials.
Academic research institutions buy laboratory testing and related research services.

En qué se apoya y qué podría romperlo

De qué depende el negocio

1Its data business depends on continued access to patient records and permission to use and commercialize de-identified data.
2Clinical testing revenue depends in part on insurers and government health programs covering tests and paying enough to cover their cost.
3Laboratory testing relies on specialized instruments and materials from a limited number of suppliers, including some sole suppliers.
4The business depends on hospitals and other healthcare providers sharing data and using Tempus tests and software.

Qué podría salir mal

1If Tempus loses access to patient data or cannot continue to use and license it, its research data and related services could be affected.
2Insurers or government health programs may decline to cover tests, reduce payment, or change reimbursement rules, affecting the amount Tempus collects for diagnostic work.
3Changes to rules for laboratory tests and AI-based medical tools could require additional approvals or oversight, delay products, or limit how Tempus can sell them.

Estados financieros completos →

Sobre Tempus AI, Inc.

Tempus runs laboratory tests that examine a patient’s cancer or inherited health risks, then connects results with medical records and other patient information. It uses artificial intelligence (AI) to help doctors interpret results and identify possible treatments or clinical trials. Drug and biotechnology companies pay Tempus for de-identified patient data, research tools, and help finding patients for trials.

Sede: Chicago, Illinois
Fundada en: 2015
Cotiza en: Nasdaq
Cierre del ejercicio: December 31

Construido a partir de los propios informes de Tempus AI, Inc. ante la Comisión de Bolsa y Valores de EE. UU. (SEC). Las cifras son las declaradas, con el historial por acción reexpresado a la base de acciones de hoy. Esto describe un negocio: no es asesoramiento de inversión ni una recomendación de compra o venta.

Keep exploring

The themes Tempus AI is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

Highest-graded in Health Information Services

Graded A or B and worth $2B or more: A first, then the largest.

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

Cómo gana dinero

Diagnostic testing75 %
Data and applications25 %

Los porcentajes de ingresos son estimaciones para nine months ended September 30, 2026, no cifras de un informe oficial.

Compite con

Caris Life Sciences

Qué vende6

Tempus|xT
A test of cancer tissue that looks for gene changes that may help doctors understand a cancer and choose treatment.
Tempus|xF
A blood test that looks for cancer-related genetic material circulating in the blood.
Tempus|xG
Tests that look for inherited gene changes linked to cancer risk and other inherited conditions.

Mostrar 3 más

Insights
De-identified patient records and research tools that drug and biotechnology companies use to study diseases and develop medicines.
TIME Trial program
A service that helps doctors and drug companies find patients who may qualify for clinical trials.
Next
Software that checks patient information to help care teams spot missed tests or follow-up needs in cancer and heart care.

Quién se lo compra4

Doctors, genetic counselors, and hospitals order tests for patients; insurers, government health programs, patients, or the ordering institution may pay.
Pharmaceutical and biotechnology companies buy de-identified patient data, research tools, and analysis services.
Drug companies pay for help identifying patients who may qualify for clinical trials.
Academic research institutions buy laboratory testing and related research services.

En qué se apoya y qué podría romperlo

De qué depende el negocio

1Its data business depends on continued access to patient records and permission to use and commercialize de-identified data.
2Clinical testing revenue depends in part on insurers and government health programs covering tests and paying enough to cover their cost.
3Laboratory testing relies on specialized instruments and materials from a limited number of suppliers, including some sole suppliers.
4The business depends on hospitals and other healthcare providers sharing data and using Tempus tests and software.

Qué podría salir mal

1If Tempus loses access to patient data or cannot continue to use and license it, its research data and related services could be affected.
2Insurers or government health programs may decline to cover tests, reduce payment, or change reimbursement rules, affecting the amount Tempus collects for diagnostic work.
3Changes to rules for laboratory tests and AI-based medical tools could require additional approvals or oversight, delay products, or limit how Tempus can sell them.

Estados financieros completos →

Sobre Tempus AI, Inc.

Sede: Chicago, Illinois
Fundada en: 2015
Cotiza en: Nasdaq
Cierre del ejercicio: December 31

Cómo gana dinero

Compite con

Qué vende6

Quién se lo compra4

En qué se apoya y qué podría romperlo

De qué depende el negocio

Qué podría salir mal

Sobre Tempus AI, Inc.

Keep exploring

Highest-graded in Health Information Services

Grade rose recently in Healthcare

Cómo gana dinero

Compite con

Qué vende6

Quién se lo compra4

En qué se apoya y qué podría romperlo

De qué depende el negocio

Qué podría salir mal

Sobre Tempus AI, Inc.

Keep exploring

Highest-graded in Health Information Services

Grade rose recently in Healthcare

Tempus AI, Inc.

Q3 2026 results

Revenue

EPS, GAAP

Operating income, GAAP

Company outlook

Crecimiento y caja — 4 de 5

Tendencia del negocio

Precio de la acción y calificación a lo largo del tiempo

Cómo gana dinero

Compite con

Qué vende6

Quién se lo compra4

En qué se apoya y qué podría romperlo

De qué depende el negocio

Qué podría salir mal

Sobre Tempus AI, Inc.

Keep exploring

Highest-graded in Health Information Services

Grade rose recently in Healthcare

Cómo gana dinero

Compite con

Qué vende6

Quién se lo compra4

En qué se apoya y qué podría romperlo

De qué depende el negocio

Qué podría salir mal

Sobre Tempus AI, Inc.

Keep exploring

Highest-graded in Health Information Services

Grade rose recently in Healthcare

Tempus AI, Inc.

Rentabilidad pasada

Q3 2026 results

Revenue

EPS, GAAP

Operating income, GAAP

Company outlook

Crecimiento y caja — 4 de 5

Tendencia del negocio

Precio de la acción y calificación a lo largo del tiempo